subject: Neurodegenerative Market Forecast To 2013 - Aarkstore Enterprise [print this page] Comprehensive Forecasts for Neurodegenerative Conditions
The neurodegenerative space is a top-selling pharmaceutical market. Consider these facts:
Sales among all drugs profiled in this report total $18.5 billion and are expected to increase 62% to $29.7 billion by 2012.
The majority of this growth is projected to be in multiple sclerosis, which will increase from a $12.6 billion market to upwards of $20 billion in 2012.
Neurodegenerative disease patients have few treatment options, which often provide only limited effectiveness. Companies that can invest in and develop new, tolerable therapies which improve patients quality of life could see hundreds of millions or even billions of dollars in sales.
In one convenient, easy-to-access format, Neurodegenerative Market Forecast to 2013 provides a compelling, full picture of the Alzheimers, Multiple Sclerosis and Parkinsons markets.
Detailed Product Profiles
CEIs veteran analysts examine 40 brands representing different classes and stages of development. The profiled products represent over 90% of sales in the neurodegenerative market. Each drug profile has the following components:
Drug history
Competitive and strategic positioning:
Current status of drug
Sales position within its class
Presence or strength of competition
Market growth opportunities:
Analysis combines new/current sales or clinical trial info with projections, predictions, insights
Analysis supported by sales projection charts, covering up to the next 7 years
